Tapemark Expands Transdermal Patch Capabilities
Tapemark recently announced the addition of several new capabilities for transdermal patches, including the formulation, blending, and coating steps in the patch manufacturing process. Combined with Tapemark’s existing converting and packaging expertise, Tapemark now is a fully integrated transdermal contract development and manufacturing organization (CDMO), from active pharmaceutical ingredients (APIs) to the finished transdermal patch.
Andy Rensink, President and Chief Operating Officer of Tapemark, explained that upon its 60th anniversary, Tapemark recently invested heavily in expanding both its capabilities and its physical facilities in the realm of transdermals.
“Responding to customer demand for full vertical integration, we’re adding formulation, blending, and coating to our existing superior converting and packaging capabilities. Now we’re a full-service provider in the transdermal space,” said Mr. Rensink.
In addition to a significant investment in new equipment and the facilities build-out currently in progress, the company is adding staff to support the new capabilities.
“The industry really has been searching for a full-service provider such as Tapemark,” added Mr. Rensink. We anticipate strong growth for Tapemark and for the pharma industry, especially as generic drugs continue their push for market share in transdermal patches.”
Tapemark is a full-service CDMO providing web-based (flexible roll goods) manufacturing for Drug, Device, and Combination Products. With new capabilities in Formulation, Blending, and Coating, added to its existing superior Converting and Packaging expertise, Tapemark is now a fully-integrated transdermal CDMO of choice, from API to finished transdermal patch. For more information, visit www.tapemark.com.
Total Page Views: 1775
